Chronic Lymphocytic Leukemia (CLL) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Chronic Lymphocytic Leukemia Pipeline Drugs Market Report Overview
Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety), and weight loss. Treatment options include surgery, radiation therapy, chemotherapy, or a combination of methods.
The CLL pipeline drugs market research report provides comprehensive information on the therapeutics under development for CLL, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for CLL and features dormant and discontinued projects.
CLL Pipeline Drugs Market Segmentation by Targets
Some of the targets of the CLL pipeline drugs market are Cells Expressing B Lymphocyte Antigen CD19, Tyrosine Protein Kinase BTK, Cells Expressing B Lymphocyte Antigen CD20, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, CD3, Cells Expressing B Cell Receptor CD22, and others.
CLL Pipeline Drugs Market Analysis, by Targets
For more CLL pipeline drugs market target insights, download a free report sample
CLL Pipeline Drugs Market Segmentation by Mechanisms of Action
Some of the key mechanisms of action of the CLL pipeline drugs market are Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Tyrosine Protein Kinase BTK Inhibitor, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, Cytotoxic To Cells Expressing B Cell Receptor CD22, B Cell Lymphoma 2 Inhibitor, CD3 Agonist, and others.
CLL Pipeline Drugs Market Analysis, by Mechanisms of Action
For more mechanisms of action insights into the CLL pipeline drugs market, download a free report sample
CLL Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the CLL pipeline drugs market are intravenous, parenteral, oral, subcutaneous, intratumor, and others.
CLL Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the CLL pipeline drugs market, download a free report sample
CLL Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the CLL pipeline drugs market are Small Molecule, Gene-Modified Cell Therapy, Monoclonal Antibody, Cell Therapy, Monoclonal Antibody Conjugated, and others.
CLL Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the CLL pipeline drugs market, download a free report sample
CLL Pipeline Drugs Market - Competitive Landscape
Some of the key companies in the CLL pipeline drugs market are Bristol-Myers Squibb Co, AbbVie Inc, BeiGene Ltd, Merck & Co Inc, Johnson & Johnson, AstraZeneca Plc, and others.
CLL Pipeline Drugs Market Analysis, by Companies
To know more about the CLL pipeline drugs market companies, download a free report sample
CLL Pipeline Drugs Market Report Overview
| Key Targets | Cells Expressing B Lymphocyte Antigen CD19, Tyrosine Protein Kinase BTK, Cells Expressing B Lymphocyte Antigen CD20, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, CD3, Cells Expressing B Cell Receptor CD22, and Others |
| Key Mechanisms of Action | Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Tyrosine Protein Kinase BTK Inhibitor, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, Cytotoxic To Cells Expressing B Cell Receptor CD22, B Cell Lymphoma 2 Inhibitor, CD3 Agonist, and Others |
| Key Routes of Administration | Intravenous, Parenteral, Oral, Subcutaneous, Intratumor, and Others |
| Key Molecule Types | Small Molecule, Gene-Modified Cell Therapy, Monoclonal Antibody, Cell Therapy, Monoclonal Antibody Conjugated, and Others |
| Key Companies | Bristol-Myers Squibb Co, AbbVie Inc, BeiGene Ltd, Merck & Co Inc, Johnson & Johnson, AstraZeneca Plc, and Others |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of CLL.
- The pipeline guide reviews pipeline therapeutics for CLL by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in CLL therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates CLL therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates CLL the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for CLL
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for all.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the CLL pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
ABL Bio Inc
Acerta Pharma BV
Achelois Cell Therapy
Actinium Pharmaceuticals Inc
Actinobac Biomed Inc
ADC Therapeutics SA
Adlai Nortye Biopharma Co Ltd
Advenchen Laboratories LLC
AI Therapeutics Inc
Alaunos Therapeutics Inc
Alloplex Biotherapeutics Inc
Amgen Inc
Apotex Inc
Ardan Pharma
Ascenta Therapeutics Inc
Ascentage Pharma Group International
Astellas Pharma Inc
AstraZeneca Plc
Athenex Inc
Aucentra Therapeutics Pty Ltd
Autolus Therapeutics Plc
Avesthagen Ltd
AVM Biotechnology LLC
BAKX Therapeutics Inc
Bantam Pharmaceutical LLC
Bayer AG
BeiGene Ltd
Beijing Gaobo Biotechnology Co Ltd
Beijing GD Initiative Cell Therapy Technology Co Ltd
Beijing Jingda Biotechnology Co Ltd
Beijing Mabworks Biotech Co Ltd
Bio-Path Holdings Inc
Biocure Technology Inc
Biogen Inc
BioIntegrator
Biomea Fusion Inc
Bionomics Ltd
BioNTech SE
BioXpress Therapeutics SA
Boryung Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
Carna Biosciences Inc
CARsgen Therapeutics Ltd
CasInvent Pharma AS
Catalent Inc
Catapult Therapeutics BV
Cellectar Biosciences Inc
Cellular Biomedicine Group Inc
Celularity Inc
Century Therapeutics Inc
Checkpoint Therapeutics Inc
Chengdu Brilliant Pharmaceutical Co Ltd
Chengdu Hyperway Pharmaceutical Co Ltd
Chengdu Jinrui Foundation Biotechnology Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chimeric Therapeutics Ltd
Chongqing Precision Biotech Co Ltd
Clonz Biotech Pvt Ltd
CoImmune Inc
Conjupro Biotherapeutics Inc
CrystalGenomics Inc
CSPC Pharmaceutical Group Ltd
Curis Inc
Cyclacel Pharmaceuticals Inc
Cyteir Therapeutics Inc
Dren Bio Inc
Eli Lilly and Co
EntreChem SL
Eternity Bioscience Inc
Eureka Therapeutics Inc
Evopoint Bioscience Co Ltd
Excelmab Inc
Exelixis Inc
Exinda Therapeutics LLC
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Fochon Pharmaceutical Ltd
Galapagos NV
GeneaMed Ltd
Genentech USA Inc
GenFleet Therapeutics (Shanghai) Inc
Genmab AS
Genor BioPharma Co Ltd
Gilead Sciences Inc
GLG Pharma SA
Grid Therapeutics LLC
Grifols SA
Grupo Ferrer Internacional SA
GSK plc
GT Biopharma Inc
Guangdong East Sunshine Pharmaceutical Co Ltd
Guangzhou BeBetter Medicine Technology Co Ltd
Guangzhou Bio-gene Technology Co Ltd
Haisco Pharmaceutical Group Co Ltd
Hangzhou Hezheng Pharmaceutical Co Ltd
Hangzhou Minsheng Pharmaceutical Group Co Ltd
Hangzhou Sumgen Biotech Co Ltd
Hangzhou Zenshine Pharmaceuticals Co Ltd
Hebei Senlang Biotechnology Co Ltd
Heidelberg Pharma AG
Helocyte Biosciences Inc
HK inno.N Corp
Hutchison MediPharma Ltd
Hybrigenics SA
iBio Inc
IDP Discovery Pharma SL
IGM Biosciences Inc
Iksuda Therapeutics Ltd
Immatics NV
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmuneTarget Inc
ImmunityBio Inc
Incyte Corp
Inflection Biosciences Ltd
InnoBation Bio
InnoCare Pharma Ltd
IO Biotech Inc
Iovance Biotherapeutics Inc
Jiangsu Maidu Drug Research and Development Co Ltd
Johnson & Johnson
Juventas Cell Therapy Ltd
Kancera AB
Kangpu Biopharmaceuticals Ltd
Kartos Therapeutics Inc
Karus Therapeutics Ltd
Karyopharm Therapeutics Inc
Kite Pharma Inc
Lanzhou Institute of Biological Products Co Ltd
LAVA Therapeutics NV
LegoChem Biosciences Inc
Light Chain Bioscience
LintonPharm Co Ltd
Loxo Oncology Inc
LTZ Therapeutics Inc
Mabion SA
ManysmarT Therapeutics Inc
MedPacto Inc
MEI Pharma Inc
MENTRIK Biotech LLC
Merck & Co Inc
Millennium Pharmaceuticals Inc
Miltenyi Biomedicine GmbH
Minghui Pharmaceutical (Shanghai) Co Ltd
MingSight Pharmaceuticals Inc
MiNK Therapeutics Inc
MorphoSys AG
Mustang Bio Inc
Nanjing Aimeifei Biomedical Technology Co Ltd
Nanjing Bioheng Biotech Co Ltd
Nanjing Iaso Biotherapeutics Co Ltd
Nanjing Sanhome Pharmaceutical Co Ltd
Newave Pharmaceutical Inc
Nichi-Iko Pharmaceutical Co Ltd
Nordic Nanovector ASA
NovalGen Ltd
Novartis AG
Nurix Therapeutics Inc
Octapharma AG
OncoTartis Inc
Oncternal Therapeutics
Ono Pharmaceutical Co Ltd
Orano Med LLC
PersonGen BioTherapeutics (Suzhou) Co Ltd
Pfizer Inc
Pharmapraxis
PIQUR Therapeutics AG
Plexxikon Inc
Precigen Inc
Precision Biosciences Inc
Qilu Pharmaceutical Co Ltd
Qilu Puget Sound Biotherapeutics Corp
Remd Biotherapeutics Inc
Repare Therapeutics Inc
Rhizen Pharmaceuticals SA
Sana Biotechnology Inc
Sanofi
Schrodinger Inc
Secura Bio Inc
SFA Therapeutics Inc
Shandong New Time Pharmaceutical Co Ltd
Shanghai Haiyan Pharmaceutical Technology Co Ltd
Shanghai Simnova Biotechnology Co Ltd
Shanghai YaKe Biotechnology Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Shengke Pharmaceuticals (Jiangsu) Ltd
Shenzhen Targetrx Inc
Shouyao Holding Co Ltd
Sian Wuhan Medical Technology Co Ltd
Sino Biopharmaceutical Ltd
Sorrento Therapeutics Inc
SpecificiT Pharma Inc
Starton Therapeutics Inc
Supratek Pharma Inc
Suzhou Fundamenta Therapeutics Co Ltd
Suzhou JiSheng Pharmaceutical Co Ltd
Swedish Orphan Biovitrum AB
Systimmune Inc
Takeda Pharmaceutical Co Ltd
Targazyme Inc
TC BioPharm Ltd
Telios Pharma Inc
TG Therapeutics Inc
Tiannuojiancheng Pharma
TransThera Sciences (Nanjing) Inc
Ubix Therapeutics Inc
United BioPharma Inc
Vincerx Pharma Inc
Viridian Therapeutics Inc
Wuhan Bio-Raid Biotechnology Co Ltd
XEME BioPharma Inc
Xencor Inc
Xi'An Yufan Biotechnology Co Ltd
Zhejiang DTRM Biopharma LLC
Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Longchuan Biomedical Technology Co Ltd
Zhejiang Teruisi Pharmaceutical Co Ltd
Zhengda Tianqing Pharmaceutical Group Co Ltd
Zibo Baiji Changsheng Pharmaceutical Co Ltd
Zylem Biosciences Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the CLL pipeline drugs market?
Some of the targets of the CLL pipeline drugs market are Cells Expressing B Lymphocyte Antigen CD19, Tyrosine Protein Kinase BTK, Cells Expressing B Lymphocyte Antigen CD20, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, CD3, Cells Expressing B Cell Receptor CD22, and others.
-
What are the key mechanisms of action in the CLL pipeline drugs market?
Some of the mechanisms of action of the CLL pipeline drugs market are Cytotoxic to Cells Expressing B Lymphocyte Antigen CD19, Tyrosine Protein Kinase BTK Inhibitor, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, Cytotoxic To Cells Expressing B Cell Receptor CD22, B Cell Lymphoma 2 Inhibitor, CD3 Agonist, and others.
-
What are the key routes of administration in the CLL pipeline drugs market?
The key routes of administration in the CLL pipeline drugs market are intravenous, parenteral, oral, subcutaneous, intratumor, and others.
-
What are the key molecule types in the CLL pipeline drugs market?
The molecule types in the CLL pipeline drugs market are Small Molecule, Gene-Modified Cell Therapy, Monoclonal Antibody, Cell Therapy, Monoclonal Antibody Conjugated, and others.
-
Which are the leading companies in the CLL pipeline drugs market?
Some of the key companies in the CLL pipeline drugs market are Bristol-Myers Squibb Co, AbbVie Inc, BeiGene Ltd, Merck & Co Inc, Johnson & Johnson, AstraZeneca Plc, and others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Sample Report
Chronic Lymphocytic Leukemia (CLL) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Oncology reports